Table 3 The results of multivariate analyses using the Cox proportional hazard model stratified by age and sex (upper column) and multivariate analyses with inclusion of age and sex (lower column)
Category, variable (reference) | Distant metastasis-free survival | Progression-free survival | Overall survival | |||
|---|---|---|---|---|---|---|
| Â | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value |
Lung V20 Gy (%), > 23.6 (≤ 23.6) | NS |  | 2.25 (1.13–4.45) | 0.01 | NS |  |
Durvalumab administration, Yes (No) | 0.31 (0.14–0.69) |  < 0.01 | 0.33 (0.15–0.69) |  < 0.01 | 0.32 (0.12–0.86) | 0.02 |
Grade 2 or higher RP, Yes (No) | 2.28 (1.02–5.10) | 0.04 | NS |  | 2.12 (0.80–5.60) | 0.13 |
Age, > 71 (≤ 71) | 0.99 (0.48–2.04) | 0.98 | 1.04 (0.55–1.97) | 0.89 | 2.19 (0.88–5.44) | 0.09 |
Sex, Male (Female) | 0.63 (0.26–1.48) | 0.29 | 0.80 (0.35–1.80) | 0.59 | 1.13 (0.35–3.60) | 0.83 |
Lung V20 Gy (%), > 23.6 (≤ 23.6) | NS |  | 2.26 (1.18–4.33) | 0.01 | NS |  |
Durvalumab administration, Yes (No) | 0.30 (0.14–0.64) |  < 0.01 | 0.33 (0.17–0.65) |  < 0.01 | 0.24 (0.09–0.66) |  < 0.01 |
Grade 2 or higher RP, Yes (No) | 2.31 (1.05–5.09) | 0.03 | NS |  | 2.19 (0.88–5.44) | 0.09 |